Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT Study - Full Text Vi
Links shared publicly online about this topic.
- 1,386total visits
Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT Study - Full Text Vi
Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT Study - Full Text View - ClinicalTrials.gov
View full resource at clinicaltrials.gov
Tags: Cancer, Lymphoma, Non-Hodgkin Lymphoma, Non-Hodgkin Lymphoma Medication, Rheumatoid Arthritis Medication, Clinical Trial, Rituxan, MabThera
Most Recently Shared on February 13, 2010 at 2:36 am By:
Multi-center US Clinical Trial (recruiting & soon to be recruiting): Bendamustine + R vs. CHOP+R for indolent lymphoma. http://bit.ly/bMVHXW
Advertisement
